CA2971583A1 - Methods of using smad7 antisense oligonucleotides - Google Patents

Methods of using smad7 antisense oligonucleotides Download PDF

Info

Publication number
CA2971583A1
CA2971583A1 CA2971583A CA2971583A CA2971583A1 CA 2971583 A1 CA2971583 A1 CA 2971583A1 CA 2971583 A CA2971583 A CA 2971583A CA 2971583 A CA2971583 A CA 2971583A CA 2971583 A1 CA2971583 A1 CA 2971583A1
Authority
CA
Canada
Prior art keywords
weeks
patient
ibd
treatment period
period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2971583A
Other languages
English (en)
French (fr)
Inventor
Scott Andrew Smith
Xiaobin Li
Guillermo ROSSITER
Philippe L. Martin
Seth R. Dewacker
Keith USISKIN
Gary Allan Cline
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nogra Pharma Ltd
Original Assignee
Celgene Alpine Investment Co II LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Alpine Investment Co II LLC filed Critical Celgene Alpine Investment Co II LLC
Publication of CA2971583A1 publication Critical patent/CA2971583A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2971583A 2014-12-26 2015-12-23 Methods of using smad7 antisense oligonucleotides Abandoned CA2971583A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462097012P 2014-12-26 2014-12-26
US62/097,012 2014-12-26
US201562235269P 2015-09-30 2015-09-30
US62/235,269 2015-09-30
PCT/US2015/000269 WO2016105516A1 (en) 2014-12-26 2015-12-23 Methods of using smad7 antisense oligonucleotides

Publications (1)

Publication Number Publication Date
CA2971583A1 true CA2971583A1 (en) 2016-06-30

Family

ID=56151259

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2971583A Abandoned CA2971583A1 (en) 2014-12-26 2015-12-23 Methods of using smad7 antisense oligonucleotides

Country Status (17)

Country Link
US (1) US20190112608A1 (de)
EP (1) EP3237018A4 (de)
JP (1) JP2018502107A (de)
KR (1) KR20170105529A (de)
CN (1) CN107405413A (de)
AU (1) AU2015371325A1 (de)
BR (1) BR112017013765A2 (de)
CA (1) CA2971583A1 (de)
CL (1) CL2017001701A1 (de)
CO (1) CO2017007383A2 (de)
EA (1) EA201791471A1 (de)
EC (1) ECSP17040003A (de)
IL (1) IL253023A0 (de)
MA (1) MA41271A (de)
MX (1) MX2017008462A (de)
SG (1) SG11201705179TA (de)
WO (1) WO2016105516A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3207136A1 (de) 2014-10-17 2017-08-23 Nogra Pharma Limited Verfahren und zusammensetzungen zur behandlung eines patienten mit einem smad7-antisense-oligonukleotid
EP3420082A4 (de) 2016-02-23 2019-10-16 Celgene Alpine Investment Company II, LLC Verfahren zur behandlung von darmfibrose mittels smad7-hemmung
WO2018112235A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
WO2018111323A1 (en) * 2016-12-14 2018-06-21 Progenity Inc. Methods and ingestible devices for the regio-specific release of smad7 inhibitors at the site of gastrointestinal tract disease
CU20200082A7 (es) 2018-05-09 2021-06-08 Ionis Pharmaceuticals Inc Compuestos y métodos para la reducción de la expresión de fxi
TWI833770B (zh) 2018-06-27 2024-03-01 美商Ionis製藥公司 用於減少 lrrk2 表現之化合物及方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4175101A (en) * 2000-02-23 2001-09-03 Univ California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
WO2003097082A2 (en) * 2002-05-17 2003-11-27 Protein Design Labs Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
ITRM20030149A1 (it) * 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
CN101568331A (zh) * 2006-09-08 2009-10-28 奥尔制药有限公司 减少或缓解消化道炎症的方法
CA2669229A1 (en) * 2006-11-17 2008-05-29 Shire Development Inc. Method of treatment for inflammatory bowel disease
WO2010020593A1 (en) * 2008-08-18 2010-02-25 Glaxo Group Limited Treatment of an autoimmune disease using il-18 antagonists
RU2593939C2 (ru) * 2008-11-13 2016-08-10 Ногра Фарма Лимитед Антисмысловые композиции и способы их получения и применения
TR201000680A2 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler
JP6389122B2 (ja) * 2011-09-15 2018-09-12 ノグラ ファーマ リミテッド 抗ｓｍａｄ７治療に対する応答性をモニターするための方法
AU2015257589A1 (en) * 2014-05-09 2016-11-24 Nogra Pharma Limited Methods for treating inflammatory bowel disease
EP3207135A2 (de) * 2014-10-17 2017-08-23 Celgene Alpine Investment Company II, LLC Isotopologe von smad7-antisense-oligonukleotiden
EP3213070A2 (de) * 2014-10-17 2017-09-06 Nogra Pharma Limited Verfahren zur dosierung und überwachung einer smad7-antisense-oligonukleotidbehandlung unter verwendung von mit biomarkerlevels

Also Published As

Publication number Publication date
MX2017008462A (es) 2018-02-26
ECSP17040003A (es) 2017-10-31
CL2017001701A1 (es) 2018-04-06
US20190112608A1 (en) 2019-04-18
SG11201705179TA (en) 2017-07-28
EP3237018A4 (de) 2018-07-11
CO2017007383A2 (es) 2018-01-05
MA41271A (fr) 2017-10-31
WO2016105516A8 (en) 2017-07-06
KR20170105529A (ko) 2017-09-19
BR112017013765A2 (pt) 2018-02-27
EP3237018A1 (de) 2017-11-01
IL253023A0 (en) 2017-08-31
EA201791471A1 (ru) 2017-12-29
WO2016105516A1 (en) 2016-06-30
CN107405413A (zh) 2017-11-28
JP2018502107A (ja) 2018-01-25
AU2015371325A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
Salas et al. JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
EP3355896A2 (de) Verfahren zur verwendung von smad7-antisense-oligonukleotiden auf der basis von biomarkerexpression
US10473669B2 (en) Methods for treating inflammatory bowel disease
US20190112608A1 (en) Methods of using smad7 antisense oligonucleotides
US20200032264A1 (en) Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
EP3503882A1 (de) Verfahren zur behandlung von fibroblastenwachstumsfaktor-19-vermittelten karzinomen und tumoren
JP7347743B2 (ja) トラジピタントによるアトピー性皮膚炎の改善された治療
MX2015004563A (es) Biomarcadores predictivos para respuesta clinica para acetato de glatiramero.
KR20170069262A (ko) Smad7 안티센스 올리고뉴클레오티드로 대상체를 치료하기 위한 방법 및 조성물
US20180015094A1 (en) Treatment of crohn's disease with delayed-release 6-mercaptopurine
KR20170031245A (ko) 염증성 장 질환을 진단 및 치료하기 위한 방법 및 조성물
EP3420085A1 (de) Verfahren zur behandlung von zöliakie mittels smad7-hemmung
KR20200005566A (ko) 염증성 장 질환의 치료에 사용하기 위한 코비톨리모드
US20200237801A1 (en) Methods of using smad7 antisense oligonucleotides based on biomarker expression
TW202043273A (zh) 用於晚期實性瘤癌症之治療性ｒｎａ
KR20220050927A (ko) 궤양성 대장염을 위한 올리고뉴클레오티드-기반 요법
TW201639591A (zh) 使用抗格拉替雷醋酸鹽抗體反應之方法
WO2023056305A1 (en) Cd40l-specific tn3-derived scaffolds for use in the treatment and prevention of rheumatoid arthritis
US20220184029A1 (en) Compositions and methods for treating neuroblastoma
JP2024020797A (ja) 筋萎縮の治療剤
JP2023553336A (ja) 自己投与のためのコビトリモド用量
Alzahrani Airway Smooth Muscle and Mast Cell Interaction Modulates Corticosteroids Sensitivity

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220315